Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors

J Clin Oncol. 2010 Aug 20;28(24):e415. doi: 10.1200/JCO.2010.29.4678. Epub 2010 Jun 21.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase I as Topic
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Intracellular Signaling Peptides and Proteins / drug effects*
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Middle Aged
  • Perivascular Epithelioid Cell Neoplasms / drug therapy*
  • Perivascular Epithelioid Cell Neoplasms / secondary
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Serine-Threonine Kinases / drug effects*
  • Protein Serine-Threonine Kinases / metabolism
  • Pyrazines / administration & dosage
  • Retroperitoneal Neoplasms / drug therapy*
  • Retroperitoneal Neoplasms / secondary
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • TOR Serine-Threonine Kinases
  • Topotecan / administration & dosage
  • Treatment Failure

Substances

  • Boronic Acids
  • Intracellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • Pyrazines
  • temsirolimus
  • Bortezomib
  • Topotecan
  • Doxorubicin
  • MTOR protein, human
  • Protein Serine-Threonine Kinases
  • TOR Serine-Threonine Kinases
  • Sirolimus